Internal Medicine Journal · 2023 · 10 citations · 93 references
MedicineHematologyOncologyCancer ImmunologyHematologic OncologyMolecular OncologyHematologic MalignanciesHematologic Malignancy TherapyLymphoid NeoplasmsMinimal Residual DiseaseNext-generation Sequencing In OncologyB-cell Lymphoma 2 InhibitionBcl2 InhibitionBruton Tyrosine KinaseConsensusHematologic Malignancy ManagementRefractory Chronic Lymphocytic LeukemiaSupportive ManagementTyrosine Kinase Inhibition
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next-generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B-cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment-naïve and relapsed/refractory disease, particularly for patients with high-risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS-CoV-2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.
93
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner, Stephan Stilgenbauer, Axel Benner et al. · New England Journal of Medicine · 2000 · 3.3K citations
Life Sciences, Genetics, Oncology +17
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text